Chief Scientific Officer · Tectonic Therapeutic, Inc. · Common Stock
Open-market sale
$181K reported value · 9.8% of prior position
Disclosed 1 business day after execution (deadline: 2)
2 prior trades recorded in this security
1 other actor traded the same direction within 14 days
No material company filing within 60 days after the trade
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 21 | Reicin AliseDirector, Chief Executive Officer | Option exercise | M | — 10.0K sh | Oct 28, 2026 traded Oct 26, 2026 | |
| 9 | Reicin AliseDirector, Chief Executive Officer | Option exercise | M | $24K 10.0K sh | Oct 28, 2026 traded Oct 26, 2026 | |
| 11 | Ruddy Marcella K.Chief Medical Officer | Tax withholding | F | $12K 525 sh | Oct 2, 2026 traded Sep 25, 2026 | |
| 15 | Schwabish MarcChief Business Officer | Tax withholding | F | $9,728 411 sh | Oct 2, 2026 traded Sep 25, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Tax withholding · 10b5-1 plan | F | $11K 444 sh | Oct 2, 2026 traded Sep 25, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $12K 536 sh | Oct 2, 2026 traded Sep 30, 2026 | |
| 8 | McNamara PeterChief Scientific Officer | Grant or award | A | — 21.0K sh | Sep 8, 2026 traded Sep 3, 2026 | |
| 15 | Lochner DanielChief Financial Officer | Grant or award | A | — 24.3K sh | Sep 8, 2026 traded Sep 3, 2026 | |
| 15 | Schwabish MarcChief Business Officer | Grant or award | A | — 17.8K sh | Sep 8, 2026 traded Sep 3, 2026 | |
| 11 | Ruddy Marcella K.Chief Medical Officer | Grant or award | A | — 24.3K sh | Sep 8, 2026 traded Sep 3, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $1,570 43 sh | Aug 26, 2026 traded Aug 25, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Option exercise · 10b5-1 plan | M | — 43 sh | Aug 26, 2026 traded Aug 25, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Option exercise · 10b5-1 plan | M | $633 43 sh | Aug 26, 2026 traded Aug 25, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Option exercise · 10b5-1 plan | M | — 43 sh | Aug 14, 2026 traded Aug 12, 2026 | |
| 1 | McNamara PeterChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $1,505 43 sh | Aug 14, 2026 traded Aug 12, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Option exercise · 10b5-1 plan | M | $633 43 sh | Aug 14, 2026 traded Aug 12, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Option exercise · 10b5-1 plan | M | — 172 sh | Jul 1, 2026 traded Jun 30, 2026 | |
| 0 | McNamara PeterChief Scientific Officer | Option exercise · 10b5-1 plan | M | $2,530 172 sh | Jul 1, 2026 traded Jun 30, 2026 | |
| 1 | McNamara PeterChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $6,020 172 sh | Jul 1, 2026 traded Jun 30, 2026 | |
| 9 | Vitorovic StefanDirector | Grant or award | A | — 10.2K sh | Jun 10, 2026 traded Jun 9, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $181,410
McNamara Peter filed this Form 4 reporting a open-market sale of TECX on Mar 6, 2026. It became public on Mar 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.